Ted Medicine ( 03880.HK ) 2025 Annual Profit: 217 million yuan, up 267.3% year over year

NightAirdropper · 2026-03-30T17:27:48+00:00

Ted Medicine announced its 2025 annual performance, with revenue reaching 570 million yuan, a year-on-year increase of 28.9%, and profits rising to 217 million yuan, up 267.3% year-on-year. In the same year, the GLP-1 receptor agonist market reached a milestone, with Eli Lilly's Tirzepatide surpassing Novo Nordisk in sales to become the world's best-selling drug.

NightAirdropper

2026-03-30 17:27:48

Abstract generation in progress

Gelonghui March 30丨Taidai Pharmaceutical (03880.HK) released its 2025 annual results. Revenue for the year ended December 31, 2025 was RMB 570 million, up 28.9% from the year ended December 31, 2024, mainly due to an increase in revenue from the FFS and FTE businesses. Profit for the year ended December 31, 2025 reached RMB 217 million, up 267.3% year over year. The increase was mainly attributable to an increase in gross profit and the fair value gains on financial liabilities measured at fair value through profit or loss. Basic earnings per share were RMB 1.63.

In 2025, the GLP-1 receptor agonist market achieved a historic milestone: Eli Lilly’s tirzepatide recorded total sales of US$36.5 billion, surpassing Novo Nordisk’s semaglutide series (US$36.1 billion) to become the world’s best-selling drug. This milestone highlights the transformational impact of dual GLP-1/GIP receptor agonists in addressing the huge unmet needs in the management of diabetes and obesity.

View Original

This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.

2 Likes